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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Ebola, Zika, Middle East respiratory syndrome (MERS),
Chikungunya, Severe Acute Respiratory Syndrome (SARS). The
cadence of emerging infectious diseases that travel, transmit and
stand ready to spark a public health emergency of international
concern seems to be accelerating. These infectious diseases cause
significant human suffering, can overwhelm unprepared health
care systems, and significantly disrupt societies and economies. It
is estimated that a severe pandemic similar to the 1918 ‘‘Spanish
flu” could nowadays cost as much as 5% of global gross domestic
product; the global cost of even a moderately severe pandemic
could be as much as US$ 570 billion, or 0.7% of global income [1].
Given the health, social and economic impact of infectious dis-
eases with pandemic potential, there has been much attention to
these microbial threats and, not surprisingly, the first question is
always, ‘‘Is there a vaccine?” But too often we find that the vaccines
we need most are not available when we need them most. A num-
ber of efforts are focused on better anticipating the vaccines that
we may need [2–6] and a global emergency fund has been pro-
posed to support accelerated vaccine development [7].
The ever present threat of influenza
The current headlines about Zika virus have replaced last year’s
headlines about Ebola. . .and next year’s headlines will undoubt-
edly feature something new. Imperfect crystal balls fail to guide
us with certainty. But looming in the background is the ever pre-
sent threat of influenza, the only microbe that causes regular wide-
spread epidemics around the world. Not so exotic and all too
familiar – casually referred to as the ‘‘flu” – influenza is the virol-
ogist’s Trojan horse, as it readily and rapidly mutates (drift), has
the ability to swap genetic elements from influenza viruses with
origins in other species (shift) and, as an RNA virus lacks repair
and self-correcting mechanisms that are the basis of its genetic
instability and makes it both dangerous and unpredictable. A reas-
sortment leading to an extremely virulent and readily transmissi-
ble pandemic virus is inevitable.
Of the many things that need to be in place to prepare for and
respond to the next influenza pandemic, vaccines – together with
the capacity to mount a timely global vaccination effort – are para-
mount. A pandemic can only be brought under control through a
shift in the population from susceptibility to immunity. But as
we learned in the 2009 influenza pandemic, although our response
time has improved, a significant shift in approach is needed if an
effective vaccine is to be in place before the next pandemic
emerges. With that goal in mind, the science of influenza and of
vaccine development needs to be looked at with fresh eyes [8].The Holy Grail is an influenza vaccine that provides a broader
and more durable immune response than the natural infection
and that can provide population immunity to pandemic influenza
viruses before they emerge. A number of efforts are now focused
on developing such a ‘‘universal” influenza vaccine; however, the
scientific challenges involved are enormous [9,10]. Until such a
universal influenza vaccine becomes available, global influenza
vaccine production capacity needs to be ready to respond when
the next pandemic emerges.
Vaccines obviously need to be safe and effective, but they
must also be available and affordable. While vaccine supply is
clearly essential for a large-scale vaccination programme, the
logistics and supporting policies needed to conduct effective
and efficient vaccination campaigns in a range of community set-
tings also need to be addressed and the needs of high-risk and
vulnerable populations and of low-and middle-income countries
accommodated. Ultimately, the success of a vaccination pro-
gramme will hinge not only on the technical aspects of its imple-
mentation, but on the demand for it among the population; this
underscores the need to understand the factors that promote vac-
cine acceptance [11,12].
Mind the GAP
Within this broad framework, and with a focus on the role of
vaccines in mitigating the impact of both seasonal and pandemic
influenza, WHO established in 2006 the Global Action Plan for
Influenza Vaccines (GAP) as ‘‘a comprehensive strategy to reduce
the present global shortage of influenza vaccines for seasonal epi-
demics and pandemic influenza in all countries of the world” [13].
The papers in this Special Issue of Vaccine, provide a foretaste of
the in-depth review to come in November 2016, when WHO will
host the third and final consultation on GAP as the programme,
as it exists today, comes to close. The background papers prepared
for this consultation are available on the WHO website (http://
www.who.int/influenza_vaccines_plan/news/gap3_Nov16/en/).
While this event is advertised as a programme review, in reality as
an examination of the progress achieved during the decade, it
should also serve to direct the global community on the path for-
ward for the work that remains to achieve global pandemic influ-
enza vaccine and vaccination preparedness.
This review, combined with the current rethinking of global
preparedness for emerging threats, the review of the Pandemic
Influenza Preparedness (PIP) Framework [14], and WHO’s restruc-
turing of its approach to global health emergencies [15], allows a
timely reassessment not only of the impact of this programme
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paredness overall.
The Global Action Plan for Influenza Vaccines was structured
around three broad objectives that underpin pandemic influenza
vaccine and vaccination preparedness:
– evidence-based increase in seasonal influenza vaccine use;
– increase in influenza vaccine production capacity and regula-
tory capacity;
– research and development for improved influenza vaccines.
The articles contained in this issue not only relate to the GAP
objectives but also reflect the principles and goals of PIP and high-
light the synergy of these two efforts. PIP’s pandemic preparedness
goal of increasing the access to vaccines and other pandemic-
related supplies by developing countries (and the critical impor-
tance of improving the sharing of influenza viruses with human
pandemic potential toward that end), will ultimately depend on
influenza vaccine production capacity in place when the next pan-
demic occurs.
These articles present a variety of perspectives on the system
that will develop, produce, regulate, distribute and evaluate pan-
demic vaccines and mass vaccination programmes. They have been
selected to represent some of the many elements of the system
that will be necessary for a pandemic vaccine response – including
clinical trials of new vaccines, new vaccine production platforms,
national regulatory systems, implementation of policy recommen-
dations for vaccine use, and assessment of the sustainability of the
global influenza vaccine manufacturing capacity that GAP has
supported.
Progress has already been significant and measurable. One clear
example is that global production of seasonal influenza vaccine
increased from less than 500 million doses in 2006 to nearly
1.5 billion doses in 2015 [16,17]. Yet, there is a pressing need for
additional burden of influenza illness studies to provide the essen-
tial data that will be looked to by policymakers to assess the role of
vaccines in national influenza control strategies. It is the imple-
mentation of these policies that will determine demand. Without
a concomitant increase in global demand for seasonal influenza
vaccine, the capacity that will produce the world’s pandemic vac-
cines that GAP has stimulated cannot be sustained [18].
At the end of the day there is the expectation that the efforts
and investments made to prepare for a pandemic will result in
the timely and equitable availability of a vaccine that is safe and
effective, and that can be used in vaccination campaigns before
the majority of the global population is exposed to the virus.
However, a continuing dedicated effort is needed to ensure that
all the elements of the system that will allow this to happen are
in place before we need them. Because we don’t know when that
day is, the global community must continue with speed and focus.
And, as WHO develops a new structure to respond for the call to be
prepared for all hazards, in its complex organizational chart pan-
demic influenza preparedness must remain front and center.References
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